A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
about
Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancerLiquid biopsy genotyping in lung cancer: ready for clinical utility?Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient PlasmaNon-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer.Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyThe potential use of urine cell free DNA as a marker for cancer.Pharmacological management of relapsed/refractory NSCLC with chemical drugs.Liquid biopsies come of age: towards implementation of circulating tumour DNA.Integrating liquid biopsies into the management of cancer.Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?Non-blood circulating tumor DNA detection in cancer.The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.Circulating DNA in EGFR-mutated lung cancer.Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer.Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Urine test for EGFR analysis in patients with non-small cell lung cancer.Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?Liquid biopsy and its role in an advanced clinical trial for lung cancer.Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.[Detection and Clinical Significance of Abundance of EGFR Mutation].Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung Cancer.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction.Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR-mutated lung adenocarcinoma.Liquid biopsy in pancreatic cancer: the beginning of a new era.T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer.Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.A Multicenter Study to Assess Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical SettingLiquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy
P2860
Q28079253-955A983C-5B89-42A4-9457-6C7027C0FF40Q33567037-457C9B59-86B1-48C8-8E6C-D749E86653BEQ33703063-228B1BB4-C472-4AA8-B454-095E5BB941B7Q37160293-AB73B351-006E-44AE-A622-51B2A053B85DQ38376337-7697537E-1BCC-4074-A947-658E7F8C8EDAQ38598893-E05D9A3C-41F3-47CA-A462-7E25387A270AQ38994581-AD7A37F2-F64B-435D-9D27-CE526F1966DCQ39095285-191D7D0E-25D5-4794-9093-D5CA2D9FF4F3Q39149201-C3235425-490A-47EF-919E-EC022B5BAA07Q39157824-016F6178-59AB-442E-92FD-BB82EA9679AAQ39430016-3D21521B-7EED-4C24-9909-8925FB332BD1Q41866575-4A296D17-B3E0-4A5B-903C-C96A8BE140CFQ42253044-F1AFE890-706D-40B8-B0BD-C4B3EBC08AA4Q42643276-BCFF259F-D3AD-4EE8-8D0D-DDF5CE5F1094Q46633214-A1ADCBD4-DD32-4391-B478-AD7B58944FC0Q46736806-565FE494-5110-48C9-9CB9-FA7412E3D662Q46917029-32CD6E2E-9B6F-4B5C-B3E0-DA571B9F5156Q46984199-56EFC2D3-8EFE-4F84-B02E-CDA72067A23CQ47108198-ED8F850E-1747-4851-8A0A-5E4D41F3BDCCQ47139758-4361F407-BAC9-4A9D-AF68-10C91835965DQ47153925-0E91989E-A26C-4970-9402-4A03F7263DEEQ47162466-222D5F1E-D41B-4F48-A86E-F454E59A8BAAQ47450308-968F8435-84E1-4406-9231-3B1607C5E3D9Q47563363-65769390-3DD1-4007-828B-430F43AE5C26Q47564108-73AC2AE1-B9D3-40D1-A5DA-8A24F224D3FBQ47883536-9489354D-0315-4C93-81FF-ED7BAB80CA48Q48098593-D452A8A7-EE5E-49D4-8063-926DC850FE69Q48562940-9DE7B594-6C69-4184-B5EE-F8178FF5DEA9Q48572902-D931C89D-3554-4BD5-AEB1-1D662FBB62A2Q49188316-5D9E6557-BCFF-47C2-B42B-ABAFD7CE2EF3Q49887989-8C2E5E20-0E5F-43B6-A196-5C89B2990CACQ52312436-6C0A24A0-F844-4AB6-A574-5273E12E8FE1Q54091429-40679C40-0406-4039-B167-FBBF1D825EEBQ54979898-80D1D84C-09E3-44C9-9760-599D98E55371Q55058129-B6603700-340C-4A35-AEBA-8BC8F8F52D8DQ55187959-2D32E3B7-7F2F-49BB-9D01-1A1620876E69Q55361062-42FE0FA2-E65A-4D51-9FEB-758525626EFCQ55401599-D7A2D318-5191-4054-9C6D-263C4F54E8B5Q58700168-3E88CDC2-ECA0-49D7-A6CD-5A02F65F1E0FQ58701272-E8ABC64C-42DD-4850-8B51-832E7CC4E548
P2860
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
A Highly Sensitive and Quantit ...... Mutations in Urine and Plasma.
@en
A Highly Sensitive and Quantit ...... Mutations in Urine and Plasma.
@nl
type
label
A Highly Sensitive and Quantit ...... Mutations in Urine and Plasma.
@en
A Highly Sensitive and Quantit ...... Mutations in Urine and Plasma.
@nl
prefLabel
A Highly Sensitive and Quantit ...... Mutations in Urine and Plasma.
@en
A Highly Sensitive and Quantit ...... Mutations in Urine and Plasma.
@nl
P2093
P1476
A Highly Sensitive and Quantit ...... Mutations in Urine and Plasma.
@en
P2093
Cecile Rose Vibat
Chris Karlovich
D Ross Camidge
David Berz
Elaina Mann
Errin Samuelsz
Geoffrey R Oxnard
Heather Wakelee
Jennifer Geis
Karena Kosco
P304
P356
10.1016/J.JTHO.2016.05.035
P577
2016-06-30T00:00:00Z